Skip to content
Back to meeting Original
Medthority· @Medthority · X·· 2 days agoScore70

ASTRIDE

Body

#ESMO26
ASTRIDE provided US data supporting serplulimab in ES-SCLC, with outcomes consistent with the phase 3 ASTRUM-005 trial.
📊 2-year OS: 32.2% vs 17.6% 📊 Median PFS: 5.4 vs 4.9 months
No new safety signals identified.
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX

18 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

Source: Medthority · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.